Clinical trialPhase 1 / Phase 2Suspended
Switch Maintenance in Pancreatic
Phase Ib Open-Label, Multicenter, Study Evaluating the Safety and Efficacy of 'Switch Maintenance' Combination Immunotherapy Using AB154, AB122, and Sotigalimab in Patients With Metastatic Pancreatic Cancer
- Outcome
- Stopped earlyEfficacy concerns. (Efficacy or futility)
- Phase
- Phase 1 / Phase 2
- Status
- Suspended
- Study type
- Interventional
- Start
- 30 November 2022
- Expected end
- 17 May 2032
- Enrollment
- 46 participants
- Sites
- 1
- Primary outcomes
- Dose-limiting toxicities-Phase 1
- Sponsor
- Other
- Results posted
- No
- Last update
- 4 June 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. The names of the study drugs involved in this study are: * Domvanalimab (also known as AB154) * Zimberelimab (also known as AB122) * APX005M
Detailed description public domain (ClinicalTrials.gov)
This is an open-label, Phase 1b/2, multicenter, randomized study evaluating the safety and efficacy of 'switch maintenance' combination immunotherapy (domvanalimab) zimberelimab and APX005M versus 'continuous maintenance' in patients with metastatic pancreatic cancer following 4-6 months of FOLFIRINOX The names of the study drugs involved in this study are: * Domvanalimab (also known as AB154) * Zimberelimab (also known as AB122) * APX005M The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. Participants will be randomized into one of two groups: * Arm A will receive domvanalimab, zimberelimab, and APX005M every two weeks through an infusion. * Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion If you are in Arm B and the drugs stop working, participants may receive the drugs given in Arm A. Participants will receive study treatment as long the disease does not worsen or there are no serious side effects for a maximum of 26 cycles (2 years) and will be followed for 12 months after the discontinue the study drugs. It is expected that about 46 people will take part in this research study. This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational drug or drugs and also tries to define the appropriate dose of the investigational drug(s) to use for further studies. Phase II clinical trials test the safety and effectiveness of an investigational drug or drugs to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved domvanalimab, zimberelimab, or APX005M as a treatment for any disease. drug regimen.